| Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors A Orlova, V Tolmachev, R Pehrson, M Lindborg, T Tran, M Sandstrom, ... Cancer research 67 (5), 2178-2186, 2007 | 237 | 2007 |
| Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine S Ahlgren, H Wållberg, TA Tran, C Widström, M Hjertman, L Abrahmsén, ... Journal of Nuclear Medicine 50 (5), 781-789, 2009 | 142 | 2009 |
| 99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors T Tran, T Engfeldt, A Orlova, M Sandström, J Feldwisch, L Abrahmsén, ... Bioconjugate chemistry 18 (6), 1956-1964, 2007 | 139 | 2007 |
| Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence T Engfeldt, A Orlova, T Tran, A Bruskin, C Widström, AE Karlström, ... European journal of nuclear medicine and molecular imaging 34, 722-733, 2007 | 120 | 2007 |
| 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule T Engfeldt, T Tran, A Orlova, C Widström, J Feldwisch, L Abrahmsen, ... European journal of nuclear medicine and molecular imaging 34, 1843-1853, 2007 | 107 | 2007 |
| Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition V Tolmachev, TA Tran, D Rosik, A Sjöberg, L Abrahmsén, A Orlova Journal of Nuclear Medicine 53 (6), 953-960, 2012 | 98 | 2012 |
| Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake T Ekblad, T Tran, A Orlova, C Widström, J Feldwisch, L Abrahmsén, ... European journal of nuclear medicine and molecular imaging 35, 2245-2255, 2008 | 90 | 2008 |
| Combined Magnetomotive ultrasound, PET/CT, and MR imaging of 68Ga-labelled superparamagnetic iron oxide nanoparticles in rat sentinel lymph nodes in vivo M Evertsson, P Kjellman, M Cinthio, R Andersson, TA Tran, R in’t Zandt, ... Scientific reports 7 (1), 4824, 2017 | 80 | 2017 |
| In Vivo Evaluation of Cysteine-Based Chelators for Attachment of 99mTc to Tumor-Targeting Affibody Molecules T Tran, T Engfeldt, A Orlova, C Widström, A Bruskin, V Tolmachev, ... Bioconjugate chemistry 18 (2), 549-558, 2007 | 80 | 2007 |
| 68Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes R Madru, TA Tran, J Axelsson, C Ingvar, A Bibic, F Ståhlberg, L Knutsson, ... American journal of nuclear medicine and molecular imaging 4 (1), 60, 2014 | 79 | 2014 |
| Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells JL Zaro, JE Vekich, T Tran, WC Shen Molecular pharmaceutics 6 (2), 337-344, 2009 | 65 | 2009 |
| Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of 99mTc-Labeled Anti-HER2 Affibody Molecules TA Tran, T Ekblad, A Orlova, M Sandstrom, J Feldwisch, A Wennborg, ... Bioconjugate chemistry 19 (12), 2568-2576, 2008 | 61 | 2008 |
| Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging TA Tran, D Rosik, L Abrahmsén, M Sandström, A Sjöberg, H Wållberg, ... European journal of nuclear medicine and molecular imaging 36, 1864-1873, 2009 | 59 | 2009 |
| Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2: 342, a potential agent for imaging of HER2 expression in malignant tumors A Orlova, T Tran, C Widström, T Engfeldt, A Eriksson Karlström, ... International journal of molecular medicine 20 (3), 397-404, 2007 | 49 | 2007 |
| 186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours A Orlova, TA Tran, T Ekblad, AE Karlström, V Tolmachev European journal of nuclear medicine and molecular imaging 37, 260-269, 2010 | 48 | 2010 |
| Protection of Kidney Function with Human Antioxidation Protein α1-Microglobulin in a Mouse 177Lu-DOTATATE Radiation Therapy Model A Kristiansson, J Ahlstedt, B Holmqvist, A Brinte, TA Tran, ... Antioxidants & redox signaling 30 (14), 1746-1759, 2019 | 31 | 2019 |
| 135La as an Auger-electron emitter for targeted internal radiotherapy J Fonslet, BQ Lee, TA Tran, M Siragusa, M Jensen, T Kibedi, ... Physics in Medicine & Biology 63 (1), 015026, 2017 | 29 | 2017 |
| Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys J Ahlstedt, TA Tran, F Strand, B Holmqvist, SE Strand, M Gram, ... American journal of nuclear medicine and molecular imaging 5 (4), 333, 2015 | 25 | 2015 |
| Human anti-oxidation protein A1M—a potential kidney protection agent in peptide receptor radionuclide therapy J Ahlstedt, TA Tran, SE Strand, M Gram, B Åkerström International journal of molecular sciences 16 (12), 30309-30320, 2015 | 22 | 2015 |
| Clinically applicable cyclotron-produced gallium-68 gives high-yield radiolabeling of DOTA-based tracers E Jussing, S Milton, E Samén, MM Moein, L Bylund, R Axelsson, ... Biomolecules 11 (8), 1118, 2021 | 20 | 2021 |
Sven-Erik StrandLund UniversityVerified email at med.lu.se
